Raymond James Financial, Inc. upgraded shares of ADMA Biologics Inc (NASDAQ:ADMA) from a market perform rating to an outperform rating in a research report released on Tuesday, MarketBeat Ratings reports. The brokerage currently has $5.00 price objective on the biotechnology company’s stock.
Separately, ValuEngine cut ADMA Biologics from a sell rating to a strong sell rating in a report on Friday, September 1st.
Shares of ADMA Biologics (NASDAQ ADMA) traded down $0.35 on Tuesday, reaching $2.85. The company had a trading volume of 479,413 shares, compared to its average volume of 60,468. The company has a debt-to-equity ratio of 2.26, a quick ratio of 1.35 and a current ratio of 2.36. ADMA Biologics has a twelve month low of $2.01 and a twelve month high of $6.10.
A hedge fund recently raised its stake in ADMA Biologics stock. Iguana Healthcare Management LLC grew its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 276.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 565,000 shares of the biotechnology company’s stock after purchasing an additional 415,000 shares during the quarter. Iguana Healthcare Management LLC owned approximately 2.19% of ADMA Biologics worth $1,740,000 as of its most recent SEC filing. Institutional investors and hedge funds own 34.55% of the company’s stock.
About ADMA Biologics
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
What are top analysts saying about ADMA Biologics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ADMA Biologics Inc and related companies.